Clinical Trials Browser

Phase 2 × Completed × MLN 8237 × Clear all

NCT02860000 2026-02-27

Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer

Phase 2 Completed

96 enrolled 34 charts

Breast Neoplasms

NCT02187991 2024-10-09

Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer

Phase 2 Completed

169 enrolled 15 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02293005 2022-10-04

Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma

Phase 2 Completed

28 enrolled 11 charts

Other solid neoplasmThoracic

Lung Neoplasms, Mesothelioma

NCT00853307 2022-04-08

MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma

Phase 2 Completed

31 enrolled 19 charts

Ovarian Neoplasms

NCT01154816 2020-05-13

Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia

Phase 2 Completed

118 enrolled 24 charts

CNSGastrointestinalLymphoidOther hematologic neoplasmSarcoma

Neuroblastoma, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02560025 2020-05-05

Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML

Phase 2 Completed

42 enrolled 12 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02109328 2019-04-11

Alisertib in Chemotherapy-pretreated Urothelial Cancer

Phase 2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02038647 2018-12-27

Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)

Phase 2 Completed

178 enrolled 27 charts

Small Cell Lung Carcinoma

NCT01091428 2018-06-04

Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer

Phase 2 Completed

191 enrolled 39 charts

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00830518 2018-05-11

A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome

Phase 2 Completed

57 enrolled 21 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00807495 2018-03-27

Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma

Phase 2 Completed

48 enrolled 18 charts

Burkitt Lymphoma, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT01799278 2018-01-23

A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer

Phase 2 Completed

60 enrolled 10 charts

Prostatic Neoplasms

NCT01653028 2017-11-30

Alisertib in Treating Patients With Advanced or Metastatic Sarcoma

Phase 2 Completed

72 enrolled 13 charts

Leiomyosarcoma, Liposarcoma, Sarcoma, Dermatofibrosarcoma, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT01466881 2016-03-10

Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma

Phase 2 Completed

42 enrolled 10 charts

LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell